Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Upstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for vereki ...

Dhaka, the overcrowded capital city of Bangladesh, has ranked 13th on the list of cities with the worst air quality, with an ...

As of late Friday morning the air quality levels around Montezuma County have reached moderate levels, according to the U.S.

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with ...

It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

A recent population-based study published in the Journal of American Medical Association identified a modest increase in ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

A comprehensive meta-analysis of over 4.3 million adults shows e-cigarette use is associated with significantly higher odds ...